FindTrial
Sign In

A study on cost of antibiotic therapy

A study to evaluate the implications of cost burden on anti-microbial resistance(AMR) using data analytics techniques.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/08/020938
Enrollment
1320
Registered
2019-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A418- Other specified sepsis

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Both Community acquired and hospital Acquired Infection Patients, Both Gram positive and Gram Negative Infections, Multiple infections and/or multiple site of infections, Direct cost

Exclusion criteria

Exclusion criteria: Incomplete susceptibility data, Incomplete financial data, Indirect cost

Design outcomes

Primary

MeasureTime frame
Difference in total spending to treat an infection and length of stay between three groups. Resistant bacterial species which caused the additional cost burden and LOS in patients. Timepoint: Every 6 months the cost expenditure and length of stay will be analysed using data analytics techniques.—

Secondary

MeasureTime frame
Total antibiotic use and resistance pattern will be observed.Timepoint: Every 6 months the pattern of bacterial resistance will be observed.—

Countries

India

Contacts

Public ContactDr Rajesh V

Manipal College of Pharmaceutical Sciences

rajesh.v@manipal.edu08202922403

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026